Akebia Therapeutics (AKBA) EPS (Basic) Growth (5y) (2018 - 2026)
Akebia Therapeutics (AKBA) EPS (Basic) Growth (5y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.18 Bn | 43.22 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.87 Bn | 2.15 Bn |
| 3 | Zoetis | 32.47 Bn | 30.79 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.62 Bn | 22.82 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.38 Bn | 19.71 Bn | 683.80 Mn |
| 6 | Viatris | 18.85 Bn | 17.96 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.52 Bn | 15.13 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.90 Bn | 11.37 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Akebia Therapeutics | 256.15 Mn | 100.60 Mn | 38.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 42.26% |
| Mar 31, 2026 | 40.10% |
| Dec 31, 2025 | 40.50% |
| Sep 30, 2025 | 14.93% |
| Jun 30, 2025 | 14.88% |
| Mar 31, 2025 | 15.49% |
| Dec 31, 2024 | 32.25% |
| Sep 30, 2024 | 26.99% |
| Jun 30, 2024 | 39.18% |
| Mar 31, 2024 | 32.34% |
| Dec 31, 2023 | 14.91% |
| Sep 30, 2023 | 29.97% |
| Jun 30, 2023 | 36.92% |
| Mar 31, 2023 | 21.30% |
| Dec 31, 2022 | 33.49% |
| Sep 30, 2022 | 12.96% |
| Jun 30, 2022 | 16.84% |
| Mar 31, 2022 | 25.52% |
| Dec 31, 2021 | 20.66% |
| Sep 30, 2021 | 19.89% |